ReviewBiosensors2026
AI/ML-Assisted SERS Biosensing for Biomolecular Detection: From Direct Spectral Response to Integrated Diagnostic Systems.
Review in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Surface-enhanced Raman scattering (SERS) offers a powerful route for biomolecular detection because it combines molecular specificity with high sensitivity, rapid optical readout, and multiplexing capability. In real biological samples, however, analytical performance is rarely determined by signal enhancement alone. Biofluids such as serum, plasma, saliva, urine, and interstitial fluid contain complex biomolecular mixtures that interfere with target capture, spectral response, and data interpretation. A practical SERS biosensor must therefore localize targets, stabilize spectral responses, tolerate matrix-induced variation, and convert complex spectra into reliable analytical information. This review discusses recent progress in SERS biosensing from an integrated system perspective, with particular focus on artificial intelligence/machine learning (AI/ML)-assisted interpretation. Direct label-free SERS provides chemically transparent readouts but is limited by stochastic adsorption, hotspot heterogeneity, and spectral variation in complex samples. Bio-recognition interfaces improve target localization, while signal-transduction strategies based on nanotags, immunoassays, clustered regularly interspaced short palindromic repeats (CRISPR) systems, nanozymes, and lateral-flow formats decouple molecular recognition from spectral generation. Digital SERS further improves measurement robustness by converting fluctuating intensities into countable, event-based outputs. AI/ML-assisted analysis can support full-spectrum classification, calibration transfer, explainability, and patient-level decision-making. We frame AI/ML-assisted SERS biosensing as an integrated architecture connecting substrate design, interface engineering, signal transduction, digital measurement, and clinical validation. Future progress will depend as much on validation-ready workflows as on plasmonic enhancement itself, especially for systems intended to operate across different samples, instruments, and clinical settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.